TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / ADARx Pharmaceuticals Stock

ADARx Pharmaceuticals Stock

adarx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $352.5MM

ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.

Buy or sell ADARx Pharmaceuticals stockLearn more about ADARx Pharmaceuticals IPO

Register To Buy and Sell Shares

For more details on financing and valuation for ADARx Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access ADARx Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ADARx Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

ADARx Pharmaceuticals investors also invested in these private companies

T. Rowe Price
Vivo Capital
OrbiMed
Ascenta Capital
Sirona Capital
Lilly Asia Ventures
SR One
TCG Crossover Management
Bain Capital Life Sciences

Team

Management Team

Zhen Li Ph.D
Co-Founder, Chief Executive Officer & President
Christopher Prentiss
Chief Financial Officer
Robert MacLeod Ph.D
Chief Scientific Officer
Rui Zhu Ph.D
Co-Founder & Vice President, Research and Development

Board Members

Chen-Ming Yu MD
TCG Crossover Management
Erez Chimovits
OrbiMed
Judith Li
Lilly Asia Ventures
Lorence Kim MD
Ascenta Capital
Ricky Sun Ph.D
Bain Capital Life Sciences
Simeon George MD
SR One Capital Management
Yuan Sun
Sirona Capital

Frequently Asked Questions About ADARx Pharmaceuticals’ Stock

plusminus
Can you buy ADARx Pharmaceuticals’ stock?
ADARx Pharmaceuticals is not publicly traded on NYSE or NASDAQ in the U.S. To buy ADARx Pharmaceuticals’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell ADARx Pharmaceuticals’ stock?
Yes, you can sell stock of a private company like ADARx Pharmaceuticals. Forge can help you sell your ADARx Pharmaceuticals stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is ADARx Pharmaceuticals’ stock price?
ADARx Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access ADARx Pharmaceuticals’ private market stock price with Forge Data.
plusminus
What is ADARx Pharmaceuticals’ stock ticker symbol?
ADARx Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like ADARx Pharmaceuticals in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Precision Neuroscience

Sector
Healthcare / BioTech & Pharma
 
 

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

BioAge

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$439.94MM

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Life Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$500MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

FIERCEBIOTECH 08/09/2023
RNA biotech ADARx hauls in $200M, almost doubling 2 previous raises combined
Who says crossover rounds are dying? ADARx has raked in a $200 million series C, almost twice as much as the previous two joint series B rounds combined. The question now is, how quickly can the biotech's RNA pipeline be expanded?
The San Diego Union-Tribune 01/31/2023
San Diego biotech lands $46M for treatment targeting life-threatening swelling attacks
ADARx Pharmaceuticals is working on an RNA precision medicine platform spanning multiple therapeutic areas.

Trending Companies

Frequently Asked Questions

Updated on: Apr 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.